Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients

Diabetes Care

Volumn 21, Issue 9, 1998, Pages 1470-1474

  Shimizu, Hiroyuki ^a,c   Tsuchiya, Takahumi ^a   Sato, Noriyuki ^a   Shimomura, Yohnosuke ^b   Kobayashi, Isao ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA PREFECTURAL COLLEGE OF HEALTH SCIENCES   (Japan)

^c Third Department of Internal Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN; TROGLITAZONE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES CONTROL; FEEDING BEHAVIOR; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUNGER; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 3543001598     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.9.1470     Document Type: Article

References (28)

1. Zhang Y, Fronca R, Maffei M, Barone M, Leopald L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue, Nature 372:425-432, 1994
2. De Vos P, Saladin R, Auwerx J, Staels B: Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J Biol Chem 270:15958-15961, 1995
3. Campfield LA, Smith FJ, Burn P: The OB protein (leptin) pathway: a link between adipose tissue mass and central neural networks. Horn Metab Res 28:619-632, 1996
4. Considine RV, Sinha MK, Heiman ML, Kriaugiunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF: Serum immunoreactive-leptin levels in normal-weight and obese humans. N Engl J Med 334:292-295, 1996
5. Shimizu H, Shimomura Y, Hayashi R, Ohtani K, Sato N, Futawatari T, Mori M: Serum leptin concentration is associated with total body fat mass, but not abdominal fat distribution. Int J Obes Relat Metab Disord 21:536-541, 1997
6. Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, Staels B, Auwerx J: Transient increase in obese gene expression after food intake or insulin administration. Nature 377:527-529, 1995
7. Kolaczynski JW, Nyce MR, Considine RV, Boden G, Nolan JJ, Henry RR, Mudaliar SR, Olefsky JM, Caro JF: Acute and chronic effect of insulin on leptin production in humans: studies in vivo and in vitro. Diabetes 45:699-701, 1996
8. Grunfeld C, Zhao C, Fuller J, Pollock A, Moser A, Friedman J, Feingold KR: Endotoxin and cytokine induce expression of leptin, the ob gene product, in hamsters. A role for leptin in the anorexia of infection. J Clin Invest 97:2152-2157, 1996
9. Shimizu H, Shimomura Y, Nakanishi Y, Futawatari T, Ohtani K, Sato N, Mori M: Estrogen increases in vivo leptin production in rats and human subjects. J Endocrinol 154:285-292, 1997
10. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
11. Nolan JJ, Lodvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
12. Kallen CB, Lazar MA: Amidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Nail Acad Sci U S A 93:5793-5796, 1996
13. Zhang B, Graziano MR Doebber TW Leibowitz MD, White-Carrington S, SzaIkowski DM, Hey PJ, Wu M, Cullinan CA, Bailey R Lollmann B, Frederich R, Flier JS, Strader CD, Smith RG: Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 271:9455-9459, 1996
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
15. Shimizu H, Saito T, Mon M: An increase of serum remnant-like particles in noninsulin-dependent diabetic patients with microalbuminuria. Gin Chim Acta 221:191-196, 1993
16. Nolan JJ, Olefsky JM, Nyce MR, Considine RV, Caro JF: Effect of troglitazone on leptin production: studies in vitro and in human subjects. Diabetes 45:1276-1278, 1996
17. Mantzoros CS, Dunaif A, Flier JS: Leptin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab 82:1687-1691, 1997
18. Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, Staels B, Auwerx J: Transient increase in obese gene expression after food intake or insulin administration. Nature 377:527-529, 1995
19. Malmstrom R, Taskinen MR, Karonen SL, Yki Jarvinen H: Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologa 39:993-996, 1996
20. Hickey MS, Houmard JA, Considine RV, Tyndall GL, Midgette JB, Gavigan KE, Weidner ML, McCammon MR, Israel RG, Caro JF: Gender-dependent effects of exercise training on serum leptin levels in humans. Am J Physiol 272:E562-E566, 1997
21. Bray GA: Reciprocal relation between the sympathetic nervous system and food intake. Brain Res Bull 27:517-520, 1991
22. Sakaguchi T, Bray GA: The effect of intrahypothalamic injections of glucose on sympathetic efferent firing rate. Brain Res Bull 18:591-595, 1987
23. Sakaguchi T, Takahashi M, Bray GA: Diurnal changes in sympathetic activity: relation to food intake and to insulin injected into the ventromedial or suprachiasmatic nucleus. Gin Invest 82:282-286, 1988
24. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP: Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 41:715-722, 1992
25. Tilly-Kiesi M, Knudsen P Groop L, Taskinen MR: Hyperinsulinemia and insulin resistance are associated with multiple abnormalities of lipoprotein subclasses in glucose-tolerant relatives of NIDDM patients: Botania Study Group. J Lipid Res 37:1569-1578, 1996
26. Fombonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, Cohen JM, Grandmottet P, Vague P, Safar ME, Eschwege E: The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO Study Group. Diabetes Care 19:920-926, 1996
27. Fanghanel G, Sanchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J: Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care 19:1185-1189, 1996
28. Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P: For the Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients: Troglitazone Study Group. Diabetologia 39:701-709, 1996